TOKYO, May 01 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported the exercise status of its 16th tranche warrant (with adjusted exercise price clause) allocated to EVO FUND for the month of April 2026.
In April, 4,160 shares were delivered based on exercised warrants, out of which 1,280 warrants were exercised during the month. As of the end of March 31, 2026, the total number of outstanding warrants was 1,489, representing an exercise ratio of 86.0%.
By the end of April, the unexercised warrants stood at 1,209 (81.0%). The exercise prices varied throughout the month, ranging from ¥416 to ¥511 per share.
Notably, there were no deliveries or transfers of treasury shares during the reporting period.
🟢 Confidence: High AI-translated content.